The United Laboratories International Holdings (UNJ) AI Stock Analysis

The United Laboratories International Holdings

(Frankfurt:UNJ)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Diversified pharmaceutical modelThe combination of finished medicines and API production gives the company multiple revenue streams across the pharmaceutical value chain. This diversification can support manufacturing scale, broaden customer exposure, and reduce reliance on any single product category over the next several quarters.

Negative Factors

Revenue and margin deteriorationThe combination of falling revenue and lower margins weakens earnings momentum and makes future growth less dependable. If this trend persists, reduced operating leverage could limit reinvestment capacity, weaken returns, and make it harder for the company to sustain prior profitability levels.

The United Laboratories International Holdings (UNJ) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 1.86B
Dividend Yield: 3.95%
Average Volume (3M): 1,350
Price to Earnings (P/E): 20.8
Beta (1Y): 0.55
Revenue Growth: -18.98%
EPS Growth: -84.27%
Country: Germany
Employees: 18,000
Sector: Healthcare
Sector Strength: 51
Industry: Drug Manufacturers - Specialty & Generic

The United Laboratories International Holdings Business Overview & Revenue Model

Company Description

The United Laboratories International Holdings Limited functions as an investment holding company with a primary focus on the pharmaceutical sector. Its multifaceted operations cover the entire lifecycle of drug development and commercialization, fro...

The United Laboratories International Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:UNJ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1681	87Outperform	HKD 12.54B	9.36	25.10%	5.11%	15.05%	20.58%
HK:1513	77Outperform	HKD 26.72B	16.30	11.32%	6.71%	-9.56%	-23.22%
HK:3320	68Neutral	HKD 29.12B	6.18	7.92%	5.17%	7.94%	52.83%
HK:0512	67Neutral	HKD 15.30B	13.45	6.61%	3.92%	7.35%	-45.49%
HK:0867	61Neutral	HKD 23.94B	13.40	8.60%	3.50%	14.80%	-2.88%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:UNJ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:UNJ	The United Laboratories International	0.77	-0.55	-41.91%
HK:0867	China Medical System Holdings	9.78	-3.69	-27.40%
HK:1513	Livzon Pharmaceutical Group Class H	23.16	-4.81	-17.20%
HK:3320	China Resources Pharmaceutical Group Ltd.	4.58	-0.11	-2.34%
HK:1681	Consun Pharmaceutical Group Ltd.	15.32	1.25	8.87%
HK:0512	Grand Pharmaceutical Group Limited	4.24	-4.23	-49.92%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

The United Laboratories International Holdings AI Stock Analysis